Caffeine for Hypoxic Ischemic Encephalopathy

NCT ID: NCT06855108

Last Updated: 2025-03-03

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 830 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-30
• Study Completion Date: 2030-07-31

Brief Summary

CHIME is a randomized, parallel-arm, double-blind, placebo-controlled trial focused on infants with hypoxic ischemic encephalopathy (HIE). The trial will recruit neonates who are diagnosed with HIE within six hours after birth based on physiologic criteria (acidosis noted on an umbilical cord or early [<1 hour] postnatal blood sample) and neurologic criteria (modified Sarnat exam consistent with encephalopathy). Following informed consent, and by six hours after birth, neonates with HIE will be randomized to one of two treatment arms and subsequently receive one 20 mg/kg dose of oral caffeine followed by two additional 10 mg/kg doses at 24-hour intervals or placebo of the same regimen (three total doses).

The goal of this clinical trial is to compare the incidence of all-cause mortality OR moderate to severe neurodevelopmental impairment (NDI) at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo. Our hypothesis is that neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.

Detailed Description

Background: One million newborns die annually due to intrapartum-related events (formerly referred to as birth asphyxia). Among survivors, intrapartum related events often lead to organ dysfunction with lasting consequences, including severe morbidity and neurodevelopmental impairment (NDI). Newborns exposed to significant intrapartum-related events can have brain injury, referred to as hypoxic ischemic encephalopathy (HIE). HIE is routinely treated with therapeutic hypothermia. However, a recent multi-national randomized controlled trial demonstrated that therapeutic hypothermia increased mortality from HIE in some contexts. Therefore, there is an urgent, unmet public health need to develop effective strategies for the treatment of HIE to prevent morbidity and mortality. Caffeine, a low-cost, readily available medication is a promising strategy for treatment of HIE given its neuroprotective, anti-inflammatory, and anti-oxidative properties. Furthermore, caffeine might have physiologic benefits beyond HIE, because a single dose of a methylxanthine (caffeine's drug class) reduces acute kidney injury in infants with HIE in settings where therapeutic hypothermia is not available.

Objective: To compare the incidence of all-cause mortality OR moderate to severe NDI at 18-22 months between neonates with HIE who are randomized to oral caffeine or placebo.

Hypothesis: Neonates with HIE who receive oral caffeine will have 10% lower incidence of all-cause mortality or moderate to severe NDI at 18-22 months compared to placebo.

Study Design: 1:1 individually randomized, parallel-arm, double-blind, placebo-controlled trial

Population: ≥ 36 week gestation and ≥1800 grams liveborn neonates who meet both physiologic and neurologic criteria for moderate to severe HIE and live in the Global Network research sites

Intervention: The intervention arm will receive one 20 mg/kg loading dose of caffeine given within 6 hours of delivery, followed by a daily dose of 10 mg/kg, given every 24 hours for 2 doses (total of 3 doses).

Comparison: The comparison arm will receive placebo using an identical dosing regimen.

Primary outcomes: All-cause mortality or moderate to severe NDI at 18-22 months of age

Sub-Studies: In conjunction with the CHIME Trial, we will embed 3 sub-studies to be conducted within subsets of CHIME participants. A sample will be chosen by convenience for each sub-study.

Pharmacokinetics Sub-study: For approximately 40 participants per Global Network research site, we will collect 2-3 blood samples during the birth hospitalization for pharmacokinetic (PK) analysis of caffeine. We will use a population PK approach to characterize the PK of infants with HIE, and to relate caffeine exposure to mortality or moderate to severe disability.

Neuro-imaging Sub-Study: For participants who are born at or follow-up in a facility with the capability of performing ultra-low-field (ULF) magnetic resonance imaging (MRI), we will obtain ULF MRI brain images during the birth hospitalization and at the 6-month follow-up visit. We will relate the findings on ULF MRI to the severity of HIE at enrollment and to the neurodevelopmental outcomes.

Omics Sub-Study: For participants for whom cord blood is available, we will obtain a sample of cord blood to be stored for future multi-omic analyses (e.g., genomic, transcriptomic, proteomic, and metabolomic). We will use multi-omics to identify molecular signatures associated with HIE.

Conditions

Hypoxic Ischemic Encephalopathy (HIE)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Caffeine citrate oral solution

Participants randomized to the oral caffeine arm will receive a single 20 mg/kg loading dose of caffeine citrate administered enterally within 6 hours after delivery, followed by a 10 mg/kg dose every 24 hours for two additional doses.

Group Type: EXPERIMENTAL

Caffeine citrate oral solution

Intervention Type: DRUG

Caffeine citrate oral solution will be used and administered by enteral route (oral or by gavage tube). The loading dose (20 mg/kg) will be administered once followed by daily doses of 10 mg per kg body weight every 24 hours for two doses. The study Standard Operating Procedures (SOPs) includes details regarding caffeine preparation based on the participant's body weight.

Oral placebo

Participants randomized to the oral placebo arm will receive a single identical placebo administered enterally within 6 hours after delivery, followed by an identical placebo dose every 24 hours for two additional doses.

Group Type: PLACEBO_COMPARATOR

Oral placebo solution

Intervention Type: DRUG

Identical placebo oral solution

Interventions

Caffeine citrate oral solution

Caffeine citrate oral solution will be used and administered by enteral route (oral or by gavage tube). The loading dose (20 mg/kg) will be administered once followed by daily doses of 10 mg per kg body weight every 24 hours for two doses. The study Standard Operating Procedures (SOPs) includes details regarding caffeine preparation based on the participant's body weight.

Intervention Type: DRUG

Oral placebo solution

Identical placebo oral solution

Intervention Type: DRUG

Other Intervention Names

Oral placebo

Eligibility Criteria

Inclusion Criteria

Infants who meet all the following criteria are eligible for enrollment as study participants:

1. Liveborn infants ≥36 weeks

2. Birth weight ≥1800 grams

3. Meets physiologic criteria for moderate to severe HIE, defined as meeting either of the following two criteria:

1. Criterion #1: Severe acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:

• pH <7.0; or
• Base Deficit ≥16 mmol/L; or
• Lactate >8 mmol/L.

2. Criterion #2: Participant must meet all of the following three criteria:

i. Moderate acidosis, defined as an umbilical cord sample or neonatal serum sample within one hour after birth demonstrating any of following criteria:

• POC pH 7.0-7.15; or
• Base Deficit 10.0-15.9 mmol/L; or
• Lactate 6-8 mmol/L.

ii. Evidence of an acute perinatal event (i.e., placental abruption, intrapartum hemorrhage, cord prolapse, severe fetal heart rate abnormality, uterine rupture).

iii. Any of the following criteria:

• 10-minute Apgar <5; or
• Need for assisted ventilation initiated at birth and continued for ≥10 minutes

4. Meets neurologic criteria for moderate to severe HIE, defined as a physical exam conducted between one and six hours after birth that meets either of the following criteria:

1. Moderate to severe encephalopathy in at least three out of six modified Sarnat categories (level of consciousness, spontaneous activity, muscle tone, posture, primitive reflexes, autonomic function); or

2. A clinical diagnosis of seizure in the first six hours after birth.

Exclusion Criteria

Infants who meet any of the following criteria are not eligible for enrollment as study participants:

1. Home births

2. Infants who cannot be enrolled, randomized and receive study medication within 6 hours post-delivery

3. Infants with a recognized major congenital anomaly or genetic syndrome that would affect their neurodevelopment.

4. Infants for whom medical care will not be provided based on the severity of their condition or any other condition that would preclude participation per clinical judgement.

5. Infant has received therapeutic hypothermia or there is a clinical plan to initiate active or passive hypothermia for the infant.

6. Infants who will be unavailable to complete follow-up visits.

7. Infants who have received caffeine after delivery.

8. Infants whom the health care team deem ineligible for the study based on likelihood to receive caffeine outside of the study protocol.

9. Enrollment in another trial that will impact participation in this trial.

• Maximum Eligible Age: 6 Hours
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RTI International

OTHER

Sponsor Role: collaborator

University of North Carolina, Chapel Hill

OTHER

Sponsor Role: collaborator

Kinshasa School of Public Health

OTHER

Sponsor Role: collaborator

Institute of Nutrition of Central America and Panama (INCAP)

UNKNOWN

Sponsor Role: collaborator

Lata Medical Research Foundation, Nagpur

OTHER

Sponsor Role: collaborator

Aga Khan University

OTHER

Sponsor Role: collaborator

University Teaching Hospital, Lusaka, Zambia

OTHER

Sponsor Role: collaborator

KLE Academy of Higher Education and Research (Deemed- to- be-University), Jawaharlal Nehru Medical College (JNMC), Belagavi, India

UNKNOWN

Sponsor Role: collaborator

Bill and Melinda Gates Foundation

OTHER

Sponsor Role: collaborator

University of Virginia

OTHER

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: collaborator

Thomas Jefferson University

OTHER

Sponsor Role: collaborator

Columbia University

OTHER

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

Sponsor Role: collaborator

NICHD Global Network for Women's and Children's Health

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Melissa Bauserman, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of North Carolina, Chapel Hill

Elizabeth M McClure, PhD

Role: PRINCIPAL_INVESTIGATOR

RTI International

Denise C Babineau, PhD

Role: PRINCIPAL_INVESTIGATOR

RTI International

Locations

ICDDR,B

Saidpur, , Bangladesh

Kinshasa School of Public Health

Kinshasa, , Democratic Republic of the Congo

Institute of Nutrition of Central America And Panama (INCAP)

Chimaltenango, , Guatemala

KLE University's J N Medical College

Belagavi, , India

Lata Medical Research Foundation

Nagpur, , India

Aga Khan University

Karachi, , Pakistan

University Teaching Hospital

Lusaka, , Zambia

Countries

Bangladesh; Democratic Republic of the Congo; Guatemala; India; Pakistan; Zambia

Central Contacts

Laura Danielle Wagner, MPH

Role: CONTACT

wagner@rti.org

+1-919-541-6000

Jennifer J Hemingway-Foday, MPH, MSW

Role: CONTACT

hemingway@rti.org

Facility Contacts

Rashidul Haque, MD

Role: primary

rhaque@icddrb.org

Antoinette Tshefu, MD, PhD, MPH

Role: primary

antotshe@yahoo.com

Adrien Lokangaka, MD, MPH

Role: backup

adrinloks@gmail.com

Manolo Mazariegos, MD, MPH

Role: primary

mmaziergos@incap.org

Shivaprasad S. Goudar, MD, MHPE

Role: primary

sgoudar@jnmc.edu

Archana Patel, MD, DNB, MSCE, PhD

Role: primary

Dr_apatel@yahoo.com

Sarah Saleem, MD

Role: primary

sarah.saleem@aku.edu

Elwyn Chomba, MBChB, DCH, MRCP

Role: primary

echomba@zamnet.zm

Other Identifiers

INV-068776

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

CP CHIME

Identifier Type: -

Identifier Source: org_study_id